Recursion Pharmaceuticals Inc Clas (RXRX)
SG&A Expenses
$151.41M
TTM · Period ending: · USD
RXRX SG&A Expenses
Latest reported$151.41Mperiod ending
Latest reported$151.41Mperiod ending
RXRX TTM SG&A Expenses ($25.26M → $151.41M)
TTM SG&A Expenses
High-resolution chart · PNG
RXRX sg&a expenses history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | SG&A Expenses (USD) |
|---|---|
| 151,409,000 | |
| 156,529,000 | |
| 176,588,000 | |
| 220,117,000 | |
| 216,246,000 | |
| 201,426,000 | |
| 178,184,000 | |
| 131,456,000 | |
| 122,898,000 | |
| 119,355,000 | |
| 110,821,000 | |
| 100,201,000 | |
| 90,490,000 | |
| 83,399,000 | |
| 81,599,000 | |
| 80,962,000 | |
| 77,164,000 | |
| 69,819,000 | |
| 57,682,000 | |
| 46,055,000 | |
| 37,329,000 | |
| 28,634,000 | |
| 25,258,000 |